Stock Scorecard
Stock Summary for Ultragenyx Pharmaceutical Inc (RARE) - $21.78 as of 6/3/2026 11:15:48 AM EST
Total Score
6 out of 30
Safety Score
37 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for RARE
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RARE
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RARE
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for RARE
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for RARE (37 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for RARE
Financial Details for RARE
Company Overview |
|
|---|---|
| Ticker | RARE |
| Company Name | Ultragenyx Pharmaceutical Inc |
| Country | USA |
| Description | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 21.78 |
| Price 4 Years Ago | 46.33 |
| Last Day Price Updated | 6/3/2026 11:15:48 AM EST |
| Last Day Volume | 2,029,040 |
| Average Daily Volume | 1,647,540 |
| 52-Week High | 42.37 |
| 52-Week Low | 18.29 |
| Last Price to 52 Week Low | 19.08% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 80.56 |
| Sector PE | 58.19 |
| 5-Year Average PE | -6.92 |
| Free Cash Flow Ratio | 12.24 |
| Industry Free Cash Flow Ratio | 28.83 |
| Sector Free Cash Flow Ratio | 25.14 |
| Current Ratio Most Recent Quarter | 2.02 |
| Total Cash Per Share | 1.78 |
| Book Value Per Share Most Recent Quarter | -0.83 |
| Price to Book Ratio | 247.70 |
| Industry Price to Book Ratio | 10.66 |
| Sector Price to Book Ratio | 8.28 |
| Price to Sales Ratio Twelve Trailing Months | 3.36 |
| Industry Price to Sales Ratio Twelve Trailing Months | 9.91 |
| Sector Price to Sales Ratio Twelve Trailing Months | 9.46 |
| Analyst Buy Ratings | 13 |
| Analyst Strong Buy Ratings | 5 |
Share Statistics |
|
| Total Shares Outstanding | 98,489,000 |
| Market Capitalization | 2,145,090,420 |
| Institutional Ownership | 104.17% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -1.02% |
| Reported EPS 12 Trailing Months | -6.10 |
| Reported EPS Past Year | -1.54 |
| Reported EPS Prior Year | -5.84 |
| Net Income Twelve Trailing Months | -609,364,000 |
| Net Income Past Year | -575,000,000 |
| Net Income Prior Year | -569,183,000 |
| Quarterly Revenue Growth YOY | -2.20% |
| 5-Year Revenue Growth | 19.95% |
| Operating Margin Twelve Trailing Months | -102.20% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 175,000,000 |
| Total Cash Past Year | 434,000,000 |
| Total Cash Prior Year | 173,729,000 |
| Net Cash Position Most Recent Quarter | 175,000,000 |
| Net Cash Position Past Year | 434,000,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -80,000,000 |
| Total Stockholder Equity Prior Year | 255,297,000 |
| Total Stockholder Equity Most Recent Quarter | -236,000,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -512,281,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -5.20 |
| Free Cash Flow Past Year | -472,000,000 |
| Free Cash Flow Prior Year | -421,679,000 |
Options |
|
| Put/Call Ratio | 0.36 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.39 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 38.34 |
| 200-Day SMA | 39.77 |
System |
|
| Modified | 6/2/2026 6:41:21 AM EST |